Novo Nordisk reports Phase 3 GLP1 results for children
Novo Nordisk said it has successful results from a Phase 3 study of its injectable GLP1 drug for children, as GLP1 weight-loss drugs are not yet approved for this group.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.